• Insite Vision Inc., of Alameda, Calif., reported top-line results from a Phase III trial of Azasite Plus and Dexasite for moderate-to-severe blepharitis. The drugs did not meet the primary endpoint of complete resolution of all signs and symptoms. They did show statistically significant improvements in signs and symptoms at 15 days. Insite Vision will meet with the FDA on Aug. 19, 2013 to review the results of the DOUBle Phase III study.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST